Legumain/pH dual-responsive lytic peptide–paclitaxel conjugate for synergistic cancer therapy

References

• Bolhassani A, Jafarzade BS, Mardani G. (2017). In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides 87:1764–63.
   Web of Science ®Google Scholar
• Cai Y, Xu Z, Shuai Q, et al. (2020). Tumor-targeting peptide functionalized PEG-PLA micelles for efficient drug delivery. Biomater Sci 8:2274–82.
   PubMed Web of Science ®Google Scholar
• Chen L, Patrone N, Liang JF. (2012a). Peptide self-assembly on cell membranes to induce cell lysis. Biomacromolecules 13:3327–33.
   PubMed Web of Science ®Google Scholar
• Chen L, Tu Z, Voloshchuk N, Liang JF. (2012b). Lytic peptides with improved stability and selectivity designed for cancer treatment. J Pharm Sci 101:1508–17.
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–82.
   PubMed Web of Science ®Google Scholar
• Deng X, Mai R, Zhang C, et al. (2021). Discovery of novel cell-penetrating and tumor-targeting peptide–drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment. Eur J Med Chem 213:113050.
   PubMed Web of Science ®Google Scholar
• Edgington LE, Verdoes M, Ortega A, et al. (2013). Functional imaging of legumain in cancer using a new quenched activity-based probe. J Am Chem Soc 135:174–82.
   PubMed Web of Science ®Google Scholar
• Fleming ND, Coleman RL, Tung C, et al. (2017). Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol 147: 41–6.
   PubMed Web of Science ®Google Scholar
• Haugen MH, Boye K, Nesland JM, et al. (2015). High expression of the cysteine proteinase legumain in colorectal cancer – implications for therapeutic targeting. Eur J Cancer 51:9–17.
   PubMed Web of Science ®Google Scholar
• He B, Tan T, Wang H, et al. (2018). Rational design of tumor microenvironment-activated micelles for programed targeting of breast cancer metastasis. Adv Funct Mater 28:1705622.
   Web of Science ®Google Scholar
• Indoria S, Singh V, Hsieh M-F. (2020). Recent advances in theranostic polymeric nanoparticles for cancer treatment: a review. Int J Pharm 582:119314.
   PubMed Web of Science ®Google Scholar
• Kim MA, Yoon SD, Lee JS, Lee C-M. (2020). Melanin-PEG nanoparticles as a photothermal agent for tumor therapy. Mater Today Commun 25:101575.
   Web of Science ®Google Scholar
• Kim S-B, Dent R, Im S-A, et al. (2017). Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 18:1360–72.
   PubMed Web of Science ®Google Scholar
• Koudelka Š, Turánek J. (2012). Liposomal paclitaxel formulations. J Control Release 163:322–34.
   PubMed Web of Science ®Google Scholar
• Kubota K, Ichinose Y, Scagliotti G, et al. (2014). Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Ann Oncol 25:529–36.
   PubMed Web of Science ®Google Scholar
• Li HJ, Du JZ, Du XJ, et al. (2016). Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci USA 113:4164–9.
   PubMed Web of Science ®Google Scholar
• Lin S, Deng F, Huang P, et al. (2015). A novel legumain protease-activated micelle cargo enhances anticancer activity and cellular internalization of doxorubicin. J Mater Chem B 3:6001–12.
   PubMed Web of Science ®Google Scholar
• Liu C, Sun CZ, Huang HN, et al. (2003). Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63:2957–64.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xiong M, Gong J, et al. (2014). Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat Commun 5:4280.
   PubMed Web of Science ®Google Scholar
• Luo S, Feng J, Xiao L, et al. (2020). Targeting self-assembly peptide for inhibiting breast tumor progression and metastasis. Biomaterials 249:120055.
   PubMed Web of Science ®Google Scholar
• Mirza Z, Karim S. (2021). Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. Semin Cancer Biol 69:226–37.
   PubMed Web of Science ®Google Scholar
• Morita Y, Araki H, Sugimoto T, et al. (2007). Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells. FEBS Lett 581:1417–24.
   PubMed Web of Science ®Google Scholar
• Mu J, Zhong H, Zou H, et al. (2020). Acid-sensitive PEGylated paclitaxel prodrug nanoparticles for cancer therapy: effect of PEG length on antitumor efficacy. J Control Release 326:265–75.
   PubMed Web of Science ®Google Scholar
• Nehate C, Jain S, Saneja A, et al. (2014). Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv 11:666–86.
   PubMed Web of Science ®Google Scholar
• Ohno Y, Nakashima J, Ohori M, et al. (2010). Association of the legumain expression pattern with prostate cancer invasiveness and aggressiveness. J Urol 183:E266.
   Web of Science ®Google Scholar
• Piao L, Li Y, Zhang H, Jiang J. (2019). Stereocomplex micelle loaded with paclitaxel for enhanced therapy of breast cancer in an orthotopic mouse model. J Biomater Sci Polym Ed 30:233–46.
   PubMed Web of Science ®Google Scholar
• Rafferty J, Nagaraj H, McCloskey AP, et al. (2016). Peptide therapeutics and the pharmaceutical industry: barriers encountered translating from the laboratory to patients. Curr Med Chem 23:4231–59.
   PubMed Web of Science ®Google Scholar
• Saadat M, Mostafaei F, Mahdinloo S, et al. (2021). Drug delivery of pH-Sensitive nanoparticles into the liver cancer cells. J. Drug Delivery Sci Technol 63:102557.
   Web of Science ®Google Scholar
• Singla AK, Garg A, Aggarwal D. (2002). Paclitaxel and its formulations. Int J Pharm 235:179–92.
   PubMed Web of Science ®Google Scholar
• Song W, Anselmo AC, Huang L. (2019). Nanotechnology intervention of the microbiome for cancer therapy. Nat Nanotechnol 14:1093–103.
   PubMed Web of Science ®Google Scholar
• Sung KE, Beebe DJ. (2014). Microfluidic 3D models of cancer. Adv Drug Deliv Rev 79–80:68–78.
   PubMed Web of Science ®Google Scholar
• Tsoi KM, MacParland SA, Ma XZ, et al. (2016). Mechanism of hard-nanomaterial clearance by the liver. Nat Mater 15:1212–21.
   PubMed Web of Science ®Google Scholar
• Tu Z, Hao J, Kharidia R, et al. (2007). Improved stability and selectivity of lytic peptides through self-assembly. Biochem Biophys Res Commun 361:712–7.
   PubMed Web of Science ®Google Scholar
• Tu Z, Volk M, Shah K, et al. (2009). Constructing bioactive peptides with pH-dependent activities. Peptides 30:1523–8.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhu L, Li G, et al. (2011). Doubly hydrophilic multiarm hyperbranched polymers with acylhydrazone linkages as acid-sensitive drug carriers. Macromol Biosci 11:1553–62.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zou X, Yang L, et al. (2014). Thermosensitive hydrogel used in dual drug delivery system with paclitaxel-loaded micelles for in situ treatment of lung cancer. Colloids Surf B Biointerfaces 122:90–8.
   PubMed Web of Science ®Google Scholar
• Yang C, Sun Y, Zhang L. (2012). Dissipative particle dynamics study on aggregation of MPEG-PAE-PLA block polymer micelles loading doxorubicin. Chin J Chem 30:1980–6.
   Web of Science ®Google Scholar
• Zhang WR, Lin YY. (2021). The mechanism of asparagine endopeptidase in the progression of malignant tumors: a review. Cells 10:1153.
   PubMed Web of Science ®Google Scholar
• Zhang Y-N, Poon W, Tavares AJ, et al. (2016). Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J Control Release 240:332–48.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang H, Tan T, et al. (2018). Rational design of nanoparticles with deep tumor penetration for effective treatment of tumor metastasis. Adv Funct Mater 28:1801840.
   Web of Science ®Google Scholar
• Zhou H, Sun H, Lv S, et al. (2017). Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release. Acta Biomater 54:227–38.
   PubMed Web of Science ®Google Scholar
• Zhu YS, Tang K, Lv J. (2021). Peptide–drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci 42:857–69.
   PubMed Web of Science ®Google Scholar